BeyondSpring Inc. (BYSI) stock

BYSINasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30

$0.60+0.00 (+0.03%)

Close on Nov 13, 2026Market cap $24.72MP/E –Yield –

BeyondSpring price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

BeyondSpring's price to sales ratio was 38.4× on Feb 29, 2024, against 54.6× a year earlier. Over the last 2 years it ranged from 16.7× to 419.0×, with a median of 38.1×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2024	Feb 29, 2024	38.4×	+12.4
2023	Dec 29, 2023	26.0×	−28.2
2022	Dec 30, 2022	54.2×	−94.4
2021	Dec 31, 2021	148.6×	–

Where these numbers come from

Parsed from the XBRL in BeyondSpring's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BYSI.

Compare: BYSI vs APLM · BYSI vs NBP · BYSI vs CBIO · BYSI vs HCM · BYSI vs SLS

Company	Revenue	Growth
HCM	$204.89M	-4.3%
CBIO	$15.00M	–
BYSI	$0	–
APLM	–	–
NBP	–	–
SLS	–	–

Company

Next earnings (est.): Mar 24, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 44
Held by institutions: 14.7%
Auditor: CBIZ CPAs P.C.
SEC CIK: 1677940

Advertisement
300 × 250

See a number that looks wrong?

BeyondSpring price to sales ratio

Price to Sales Ratio at the end of each year

More BeyondSpring figures